Diagnostics

A personalized circulating tumor DNA (ctDNA) test may help detect minimal residual disease (MRD) and predict relapse earlier in patients with osteosarcoma, according to a new study. Researchers created a custom blood test for each patient by sequencing their tumor and tracking its unique genetic mutations over time. Personalized ctDNA panels were successfully developed for […]

Researchers are studying how colorectal cancer begins before tumors develop. Using Lynch syndrome, an inherited condition that can raise colorectal cancer risk to as high as 80%, they explored how the immune system responds to early cancer-related changes. In a study published in the journal Nature Communications, scientists analyzed blood samples from 277 participants and

The FDA has approved an abbreviated new drug application for a generic version of gallium Ga 68 gozetotide injection (Ga-68 PSMA-11), a PET imaging agent used to detect PSMA-positive lesions in prostate cancer. Developed by RadioMedix, this radioactive tracer supports more precise staging and detection of metastatic or recurrent disease. The approval followed a successful

The U.S. FDA has approved FoundationOne CDx, a tissue-based companion diagnostic test, to identify patients with PIK3CA-mutated, hormone receptor–positive, HER2-negative advanced or metastatic breast cancer who may benefit from treatment with inavolisib (Itovebi) combined with palbociclib (Ibrance) and fulvestrant (Faslodex). The approval provides an important alternative to the previously authorized blood-based FoundationOne Liquid CDx, helping

A new expert framework highlights how tissue next-generation sequencing (NGS) and liquid biopsy (ctDNA) should be used together in metastatic colorectal cancer rather than as interchangeable tests. Experts recommend ordering both at diagnosis because chemotherapy can quickly reduce ctDNA shedding, making later liquid biopsies less informative. Tissue testing captures the local tumor environment, while ctDNA

On May 1, 2026, the FDA approved vepdegestrant (Veppanu) for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. At the same time, the Guardant360 CDx was approved as a companion diagnostic to detect these mutations using a simple blood test. The approval is based on the Phase 3 VERITAC-2 trial, which compared vepdegestrant

Scientists have developed a new blood test that uses nanotechnology and electrical signals to detect pancreatic cancer with high accuracy. Led by Stuart Ibsen, the test uses a microchip that applies a small electric charge to blood samples to capture tumor-derived nanoparticles. These particles are then labeled to identify cancer-specific biomarkers. In a blinded study, the

Researchers at the Mayo Clinic have developed a new blood test that could improve the detection of germ cell tumors, the most common type of testicular cancer. This method is designed to find cancers that are often missed by standard tumor marker tests. The study introduced two tools based on immune system signals. One test,

Researchers have identified a promising new blood test that may help detect colorectal cancer using a specialized protein called SubB2M to measure a sugar molecule known as Neu5Gc. The test addresses limitations of current screening methods. Colonoscopies are effective but invasive, while stool-based tests can miss early disease. Existing blood markers such as CEA and

The U.S. Food and Drug Administration has accepted the resubmitted New Drug Application for TLX101-Px, also known as Pixclara, a new PET imaging agent designed to better detect and evaluate brain tumors in both adults and children. One of the biggest challenges in treating gliomas is telling the difference between true tumor growth and changes